GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair" development programme
24-Sep-2010 -
GlaxoSmithKline Plc (GSK) and Theravance, Inc. announced results from a Phase II safety and efficacy study for developmental combination treatment Relovair in chronic obstructive pulmonary disorder (COPD). Relovair is an investigational drug which combines fluticasone furoate (FF; an inhaled ...
asthma
GSK
lung function